Health Press Release – Newsletter for January 11, 2011

Takeda San Francisco and Pieris Sign Anticalin(R) Therapeutic Collaboration

SAN FRANCISCO and FREISING, Germany, January 10, 2011 – Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery
partnership agreement under which Pieris will apply its Anticalin(R) scaffold
technology to deliver protein therapeutic candidates to Takeda, both
companies announced today. The deal initially will focus on first-in-class
drug discovery efforts around a predetermined Takeda target. [..] Read the original article: here.

Over 700 Elsevier Science & Technology Books Now Available in Research4Life

Leading Publisher Offers Electronic Books to UN Program Providing Research Access to the Developing World

BURLINGTON, Massachusetts, January 10, 2011 – Burlington, MA, 10 January 2011 – Elsevier, a world-leading publisher of
scientific, technical and medical information products and services, today
announced that 780 of its science and technology electronic books will be
added to Research4Life (www.research4life.org/). Elsevier … Read : Over 700 Elsevier Science & Technology Books Now Available in Research4Life.

Interim Results From Mesoblast’s Phase 2 Heart Failure Trial Shows ‘Off-the-Shelf’ Proprietary Adult Stem Cell Product Revascor(TM) Reduces Cardiac Events, Mortality, and Hospitalization

FRAZER, Pennsylvania and MELBOURNE, Australia, January 10, 2011 – Cephalon, Inc. (Nasdaq: CEPH) and Mesoblast Limited (ASX: MSB; OTC ADR:
MBLTY) today announced positive interim results from Mesoblast's ongoing
multi-center Phase 2 trial of its "off-the-shelf" proprietary adult stem cell
product Revascor(TM) for patients with congestive heart failure. Patients who
received a single injection of Revascor(TM) into damaged … Read more »».

Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring

CARLSBAD, California, January 10, 2011 – Excaliard Pharmaceuticals, Inc., today announced results from three Phase
2 clinical trials of EXC 001 in skin scarring. EXC 001 is an antisense
oligonucleotide designed to interrupt the process of fibrosis by inhibiting
expression of connective tissue growth factor (CTGF). The three studies
demonstrated EXC 001's efficacy in elective revision surgery of …. Original article on Gaea Times at  : Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring.

Avexxin Closes Financing Round

Financing Will be Used to Develop Avexxin's Lead Compound Against Psoriasis Through Clinical Phase I/IIa

TRONDHEIM, Norway, January 10, 2011 – Avexxin AS, a Norwegian pharma company focusing on the
development of novel small molecule therapeutics for patients suffering from
chronic inflammatory conditions, announces the closure of a financing round
enabling the company to take its lead compound …. Original source  : Avexxin Closes Financing Round.

Abbott Receives CE Mark Approval for World’s First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease

Abbott's Newest Innovation Can Treat a Patient's Blocked Heart Vessel and Then Dissolve, Leaving the Patient's Vessel Free of a Permanent Metallic Implant

ABBOTT PARK, Illinois, January 10, 2011 – Abbott (NYSE: ABT) announced today that it has received CE Mark approval
for the world's first drug eluting bioresorbable vascular scaffold (BVS) for
the treatment of coronary … Read : Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease.

Health Robotics Expands i.v.STATION(R) Footprint in North America With Children’s Hospital of Los Angeles

BOZEN, SUD-TIROL, Italy, January 10, 2011 – Health Robotics today announced its first 2011 contract for the
installation of 2 i.v.STATION robots at Children's Hospital of Los Angeles,
marking the third California hospital, after Cottage Health System and
Memorial Care, to purchase 2 i.v.STATIONs each. The installation of the 2
i.v.STATIONs is scheduled to occur during 1Q2011 initially …. Read the original article  : Health Robotics Expands i.v.STATION(R) Footprint in North America With Children's Hospital of Los Angeles.

New Treatment to Improve Vision Loss for People With Diabetes

For UK Media Only
FRIMLEY, England, January 11, 2011 – Novartis Pharmaceuticals UK Ltd today announced that
Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of
visual impairment due to diabetes, specifically diabetic macular oedema
(DMO). This offers fresh hope for people with this serious and common
complication of diabetes. Ranibizumab is the first licensed therapy …. Original source  : New Treatment to Improve Vision Loss for People With Diabetes.